Skip to main content

Table 3 Multivariate analysis in overall patients according to AJCC or BCLC tumor stage

From: Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation

Characteristics

Hazard ratio (95% CI)

P value*

AJCC Tumor stage

2.775 (1.815-4.243)

< 0.001

Portal vein thrombosis

1.573 (0.912-2.715)

0.103

Serum AFP (≥ 400 ng/mL)

1.153 (0.688-1.919)

0.584

Serum PIVKA-II (≥ 300 mAU/mL)

2.718 (1.535-4.812)

0.001

Platelet count (≤ 130 × 103/μL)

1.830 (1.130-2.964)

0.014

BCLC Tumor stage

1.210 (1.047-1.400)

0.010

Portal vein thrombosis

1.934 (1.094-3.422)

0.023

Serum AFP (≥ 400 ng/mL)

1.470 (0.888-2.433)

0.133

Serum PIVKA-II (≥ 300 mAU/mL)

3.688 (2.073-6.560)

< 0.001

Platelet count (≤ 130 × 103/μL)

1.911 (1.187-3.076)

0.008

  1. Abbreviation: AFP, alpha-fetoprotein; PIVKA-II, Protein induced by vitamin K absence or antagonist-II;
  2. *P-values for each clinical variable calculated using Cox regression analysis.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us